FLNA
FLNA clinical trials: FILANA THERAPEUTICS, INC.
Every trial on ClinicalTrials.gov where FILANA THERAPEUTICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 25
- Trials linked
- 25
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
FLNA on the catalyst calendar · FLNA registry changes
- Primary completion Dec 30, 2024ActualPhase 3NCT05026177Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's DiseaseCassava Sciences, Inc. · Alzheimer DiseaseTerminatedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2024ActualPhase 2NCT05352763Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's DiseaseCassava Sciences, Inc. · Alzheimer's DiseaseTerminatedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2025ActualPhase 3NCT05575076Open-label Extension for Phase 3 Clinical Trials of SimufilamCassava Sciences, Inc. · Alzheimer DiseaseTerminatedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2, 2024ActualPhase 3NCT04994483Simufilam 100 mg for Mild-to-Moderate Alzheimer's DiseaseCassava Sciences, Inc. · Alzheimer DiseaseCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 9, 2023ActualPhase 2NCT04388254Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease PatientsCassava Sciences, Inc. · Alzheimer DiseaseCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 27, 2024ActualPhase 1NCT06195319Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male SubjectsCassava Sciences, Inc. · AbsorptionCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2024ActualPhase 1NCT06390410A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic FunctionCassava Sciences, Inc. · Hepatic InsufficiencyCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2021ActualPhase 1NCT04932655Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy VolunteersCassava Sciences, Inc. · Healthy VolunteersCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2020ActualPhase 2NCT04079803PTI-125 for Mild-to-moderate Alzheimer's Disease PatientsCassava Sciences, Inc. · Alzheimer DiseaseCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 8, 2019ActualPhase 2NCT03748706PTI-125 for Mild-to-moderate Alzheimer's Disease PatientsPain Therapeutics · Alzheimer DiseaseCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 9, 2017ActualPhase 1NCT03784300A Safety Study of PTI-125 in Healthy VolunteersPain Therapeutics · Alzheimer Disease, Early OnsetCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2017ActualPhase 1NCT03475862Nasal Human Abuse Potential of PTI-821Pain Therapeutics · Opioid Abuse NondependentCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 1NCT02165930Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy VolunteersPain Therapeutics · HealthyCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 1NCT02117583Effects of Food on Oxycodone Pharmacokinetics in Healthy VolunteersPain Therapeutics · HealthyCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2014ActualPhase 1NCT02089295Dose Proportionality Study Of PF-00345439 Formulation Under Fed ConditionsPain Therapeutics · HealthyCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2014ActualPhase 1NCT02059915Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted ConditionsPain Therapeutics · HealthyCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 1NCT01986283Abuse Potential Study of PF-00345439Pain Therapeutics · Opioid UsersCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2009ActualPhase 2NCT00734461Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug AbusePain Therapeutics · Opioid-Related DisordersCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2013ActualPhase 1NCT01924676Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy VolunteersPain Therapeutics · HealthyCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2013ActualPhase 1NCT01717027Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy VolunteersPain Therapeutics · HealthyCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2008ActualPhase 3NCT01559701Long-term Safety of PF-00345439 (Oxycodone)Pain Therapeutics · PainCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2012ActualPhase 1NCT01552863A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy VolunteersPain Therapeutics · PainCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2012ActualPhase 1NCT01552850Pharmacokinetics And Relative Bioavailability Study Of OxycodonePain Therapeutics · PainCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2010ActualPhase 1NCT00734188Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic MelanomaPain Therapeutics · Metastatic MelanomaCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2008ActualPhase 1NCT00399113Safety Study of 188Re-PTI-6D2 in Patients With Metastatic MelanomaPain Therapeutics · Metastatic MelanomaCompletedFLNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner